These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 36584499)

  • 21. Long Non-Coding RNA XLOC_006753 Promotes the Development of Multidrug Resistance in Gastric Cancer Cells Through the PI3K/AKT/mTOR Signaling Pathway.
    Zeng L; Liao Q; Zou Z; Wen Y; Wang J; Liu C; He Q; Weng N; Zeng J; Tang H; Fang R; Lei Z; Tang Z; Yang X; Cui S
    Cell Physiol Biochem; 2018; 51(3):1221-1236. PubMed ID: 30481766
    [TBL] [Abstract][Full Text] [Related]  

  • 22. circPARD3 drives malignant progression and chemoresistance of laryngeal squamous cell carcinoma by inhibiting autophagy through the PRKCI-Akt-mTOR pathway.
    Gao W; Guo H; Niu M; Zheng X; Zhang Y; Xue X; Bo Y; Guan X; Li Z; Guo Y; He L; Zhang Y; Li L; Cao J; Wu Y
    Mol Cancer; 2020 Nov; 19(1):166. PubMed ID: 33234130
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance.
    Ediriweera MK; Tennekoon KH; Samarakoon SR
    Semin Cancer Biol; 2019 Dec; 59():147-160. PubMed ID: 31128298
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recent nanotechnological interventions targeting PI3K/Akt/mTOR pathway: A focus on breast cancer.
    Sharma V; Sharma AK; Punj V; Priya P
    Semin Cancer Biol; 2019 Dec; 59():133-146. PubMed ID: 31408722
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High Sensitivity of Circulating Tumor Cells Derived from a Colorectal Cancer Patient for Dual Inhibition with AKT and mTOR Inhibitors.
    Smit DJ; Cayrefourcq L; Haider MT; Hinz N; Pantel K; Alix-Panabières C; Jücker M
    Cells; 2020 Sep; 9(9):. PubMed ID: 32962206
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comprehensive Characterization of Circular RNAs in Neuroblastoma Cell Lines.
    Zhang L; Zhou H; Li J; Wang X; Zhang X; Shi T; Feng G
    Technol Cancer Res Treat; 2020; 19():1533033820957622. PubMed ID: 33000697
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FOXK1 promotes malignant progression of breast cancer by activating PI3K/AKT/mTOR signaling pathway.
    Li ZQ; Qu M; Wan HX; Wang H; Deng Q; Zhang Y
    Eur Rev Med Pharmacol Sci; 2019 Nov; 23(22):9978-9987. PubMed ID: 31799667
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Circular RNA_0000326 promotes bladder cancer progression via microRNA-338-3p/ETS Proto-Oncogene 1/phosphoinositide-3 kinase/Akt pathway.
    Chen Y; Wang D; Shu T; Sun K; Zhao J; Wang M; Huang Y; Wang P; Zheng H; Cai Z; Yang Z
    Bioengineered; 2021 Dec; 12(2):11410-11422. PubMed ID: 34889689
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Circular RNA circ-PLCD1 functions as a tumor suppressor in non-small cell lung cancer by inactivation of PI3K/AKT signaling pathway.
    Si J; Jin J; Sai J; Liu X; Luo X; Fu Z; Wang J
    Hum Cell; 2022 May; 35(3):924-935. PubMed ID: 35301686
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Circular RNA circRHOBTB3 inhibits ovarian cancer progression through PI3K/AKT signaling pathway.
    Sun Y; Liu Y; Chen H; Tan Y
    Panminerva Med; 2024 Mar; 66(1):36-46. PubMed ID: 32720791
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The PI3K/AKT/mTOR pathway is activated in gastric cancer with potential prognostic and predictive significance.
    Tapia O; Riquelme I; Leal P; Sandoval A; Aedo S; Weber H; Letelier P; Bellolio E; Villaseca M; Garcia P; Roa JC
    Virchows Arch; 2014 Jul; 465(1):25-33. PubMed ID: 24844205
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibitory role of large intergenic noncoding RNA-ROR on tamoxifen resistance in the endocrine therapy of breast cancer by regulating the PI3K/Akt/mTOR signaling pathway.
    Lu PW; Li L; Wang F; Gu YT
    J Cell Physiol; 2019 Feb; 234(2):1904-1912. PubMed ID: 30145819
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer.
    Ciruelos Gil EM
    Cancer Treat Rev; 2014 Aug; 40(7):862-71. PubMed ID: 24774538
    [TBL] [Abstract][Full Text] [Related]  

  • 34. KRAS gene silencing inhibits the activation of PI3K-Akt-mTOR signaling pathway to regulate breast cancer cell epithelial-mesenchymal transition, proliferation and apoptosis.
    Zhang Y; Liu JL; Wang J
    Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3085-3096. PubMed ID: 32271426
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel approaches for molecular targeted therapy of breast cancer: interfering with PI3K/AKT/mTOR signaling.
    Grunt TW; Mariani GL
    Curr Cancer Drug Targets; 2013 Feb; 13(2):188-204. PubMed ID: 23215720
    [TBL] [Abstract][Full Text] [Related]  

  • 36. STX3 represses the stability of the tumor suppressor PTEN to activate the PI3K-Akt-mTOR signaling and promotes the growth of breast cancer cells.
    Nan H; Han L; Ma J; Yang C; Su R; He J
    Biochim Biophys Acta Mol Basis Dis; 2018 May; 1864(5 Pt A):1684-1692. PubMed ID: 29408595
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PI3K/Akt/mTOR Intracellular Pathway and Breast Cancer: Factors, Mechanism and Regulation.
    Sharma VR; Gupta GK; Sharma AK; Batra N; Sharma DK; Joshi A; Sharma AK
    Curr Pharm Des; 2017; 23(11):1633-1638. PubMed ID: 27848885
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Circular RNA CirCHIPK3 promotes cell proliferation and invasion of breast cancer by sponging miR-193a/HMGB1/PI3K/AKT axis.
    Chen ZG; Zhao HJ; Lin L; Liu JB; Bai JZ; Wang GS
    Thorac Cancer; 2020 Sep; 11(9):2660-2671. PubMed ID: 32767499
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Circ-PRMT5 promotes breast cancer by the miR-509-3p/TCF7L2 axis activating the PI3K/AKT pathway.
    Wu D; Jia H; Zhang Z; Li S
    J Gene Med; 2021 Feb; 23(2):e3300. PubMed ID: 33277756
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CircZNF215 promotes tumor growth and metastasis through inactivation of the PTEN/AKT pathway in intrahepatic cholangiocarcinoma.
    Liao W; Du J; Li L; Wu X; Chen X; Feng Q; Xu L; Chen X; Liao M; Huang J; Yuan K; Zeng Y
    J Exp Clin Cancer Res; 2023 May; 42(1):125. PubMed ID: 37198696
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.